Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616001487404
Ethics application status
Approved
Date submitted
20/10/2016
Date registered
26/10/2016
Date last updated
6/10/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
The Act-F Trial: Does active follow-up of invitation lead to higher participation in bowel screening by Maori, Pacific and Asians?
Scientific title
A randomised controlled trial of the impact on participation rates in the Waitemata bowel screening pilot of existing active follow-up procedures for Maori, Pacific and Asians who do not initially respond to an invitation for bowel screening
Secondary ID [1] 290361 0
NONE
Universal Trial Number (UTN)
UTN: U111111874682
Trial acronym
Act-F
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal cancer 300651 0
Immunochemical faecal occult blood screening for colorectal cancer 300652 0
Condition category
Condition code
Cancer 300499 300499 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Public Health 300500 300500 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention consists of a delay of 8 weeks in commencing the standard Active Follow (AF) pathway invitees to bowel screening who have not returned a test kit within 4 weeks of being sent an invitation letter. The standard AF service consists of the following. Eligible individuals are identified and extracted from the Bowel Screening Pilot register. This data is inserted into an Access (Registered Trademark) database. The database is available to the team of Community coordinators who carry out the AF activities. They use the database to filter the population according to the ethnicity that they serve. The Coordination Centre employs 0.4 FTE of Maori Community Coordinators, 0.4 FTE of Samoan/Other Pacific Coordinators and 0.9 FTE of Asian Coordinators. They phone the individuals and record the outcome of the calls. Key Performance Indicators set by the MOH require a minimum of 3 phone calls to be made within a 4 week period, one of which must be made after regular working hours. If a number appears to be invalid other data sources are searched for current contact details. These include the hospital systems, the Primary Health Organisation age/sex registers, the patient’s GP practice, and contacts the Community Coordinators have with their own communities. In the intervention group this active follow-up activity commences 12 weeks after being sent an invitation letter for bowel screening rather than 4 weeks after as in the control group.
Intervention code [1] 296175 0
Early detection / Screening
Comparator / control treatment
The control group is the standard (not delayed) active follow-up pathway as described above. This commences 4 weeks after being sent an invitation letter among those eligible for active follow-up (Maori, Pacific and Asian ethnicity invitees).
Control group
Active

Outcomes
Primary outcome [1] 299928 0
The primary endpoint of the study is the overall difference in the participation rate of people in the intervention group compared with the control group,
Timepoint [1] 299928 0
For each invitee, the primary outcome will be measured at 8 weeks from the date at which they were randomly assigned to the group (and for the intervention group with delayed AF, it will measured prior to their receiving the AF service).
Secondary outcome [1] 328563 0
Ethnic specific differences in the participation rate.
Timepoint [1] 328563 0
As for the primary endpoint, the secondary endpoint will be measured at 8 weeks from the time of randomisation.
Secondary outcome [2] 328589 0
Differences in participation rate according to whether the active follow-up service was provided by the Bowel Screening Coordination Centre or a contracted provider
Timepoint [2] 328589 0
Measured at 8 weeks following randomisation

Eligibility
Key inclusion criteria
All subjects will be recruited from the universe of population eligible for participation in the Waitemata Bowel Screening Pilot. This is (currently) men and women aged 50-74 who are eligible for publicly funded healthcare resident in the geographical area covered by Waitemata District Health Board. If the invitee has not returned a test kit within 4 weeks of the date of invitation, then s/he is sent a reminder letter. In addition, if that individual is recorded to have a Maori, Pacific or Asian ethnicity, then they are entered in the AF pathway. These are the individuals who are eligible to take part in the study.
Minimum age
50 Years
Maximum age
74 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
None other than those which make the invitees ineligible for the active follow-up pathway. Viz. returning a kit within 4 weeks of being sent and invitation or non-Maori, non-Pacific and non-Asian (prioritised) ethnicity.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be ensured by adherence to a strict randomisation protocol. A master randomisation key of 10,000 rows will be provided to the Project Manager to import as an Access (Registered Trademark) database. Three times per week, invitees whose test kits were sent out 28 days or more previously and who have not yet returned a test kit will be extracted from the Bowel Screening Pilot Register into an Access (Registered Trademark) database. An access table will be formed of those eligible for AF (i.e. with a prioritised ethnicity recorded as Maori, Pacific or Asian) and this will be appended into the master randomisation key in alphabetical order of the NHI numbers within that batch. The treatment allocation (intervention or control) corresponding to each individual will be copied into that person’s record, and those assigned to the control group will be allocated today’s date as their start date and will be available immediately for follow-up phone calls.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created in an excel file by its random number generator, with numbers between 0 and 1 rounded down to 0 if less than 0.5 (control group) and up to 1 if above 0.5 (intervention group).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size calculations have been performed considering the trial either as a test of non-inferiority of the intervention (delayed AF) and alternatively as a test of superiority of the control group (immediate AF). In both cases a difference of 5% in the overall participation rate was the critical limit being tested. To perform these sample size calculations it was first necessary to determine what difference in participation during AF would lead to a 5% difference in overall participation, based on the historical (2015) participation within 30 days and during the first 8 weeks of the Active Follow-up period. Sample size calculations were based on power of 90% and 95% confidence limits. Additional detail is available in the study protocol or upon request.

Analysis will be performed on an intention to treat basis. That is the endpoints will be compared for the two groups as defined from the point of randomisation to intervention or control groups and even participants who are no longer living in the DHB or who are not contactable will be included in the analysis. The initial analysis of data will test for any deviations from balance between the two groups by comparing the distribution of basic demographic variables in each. Differences in participation rates between the two groups will be tested by simple bivariate methods (e.g. the Chi square test) and also by logistic regression analysis to permit statistical control for potential confounding variables (age, sex, ethnicity, provider of active follow-up service, time period etc.).

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
7/11/2016
Actual
9/11/2016
Date of last participant enrolment
Anticipated
26/05/2017
Actual
3/04/2017
Date of last data collection
Anticipated
Actual
29/05/2017
Sample size
Target
7224
Accrual to date
Final
7690
Recruitment outside Australia
Country [1] 8337 0
New Zealand
State/province [1] 8337 0
Auckland

Funding & Sponsors
Funding source category [1] 294743 0
Government body
Name [1] 294743 0
Waitemata District Health Board
Country [1] 294743 0
New Zealand
Primary sponsor type
Individual
Name
Debbie Holdsworth
Address
Planning Funding and Outcomes Unit
Auckland and Waitemata District Health Boards
Level 2
15 Shea Terrace
Takapuna
Auckland 0622
Country
New Zealand
Secondary sponsor category [1] 293592 0
None
Name [1] 293592 0
Address [1] 293592 0
Country [1] 293592 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 296160 0
Northern A Health and Disability Ethics Committee
Ethics committee address [1] 296160 0
Ethics committee country [1] 296160 0
New Zealand
Date submitted for ethics approval [1] 296160 0
23/09/2016
Approval date [1] 296160 0
19/10/2016
Ethics approval number [1] 296160 0
16/NTA/159

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes
Attachments [1] 1191 1191 0 0
/AnzctrAttachments/371688-HDEC Letter - 16NTA159 - Approved Full Application.pdf (Ethics approval)

Contacts
Principal investigator
Name 69810 0
Dr Peter Sandiford
Address 69810 0
Health Gain Team
Planning Funding and Outcomes
Auckland and Waitemata District Health Boards
Level 1
15 Shea Terrace
Takapuna
Auckland 0622
Country 69810 0
New Zealand
Phone 69810 0
+6494868920
Fax 69810 0
Email 69810 0
[email protected]
Contact person for public queries
Name 69811 0
Peter Sandiford
Address 69811 0
Health Gain Team
Planning Funding and Outcomes
Auckland and Waitemata District Health Boards
Level 1
15 Shea Terrace
Takapuna
Auckland 0622
Country 69811 0
New Zealand
Phone 69811 0
+6494868920
Fax 69811 0
Email 69811 0
[email protected]
Contact person for scientific queries
Name 69812 0
Peter Sandiford
Address 69812 0
Health Gain Team
Planning Funding and Outcomes
Auckland and Waitemata District Health Boards
Level 1
15 Shea Terrace
Takapuna
Auckland 0622
Country 69812 0
New Zealand
Phone 69812 0
+6494868920
Fax 69812 0
Email 69812 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.